Inflammatory bowel disease 1; IBD1

Disease ID:1028
Name:Inflammatory bowel disease 1; IBD1
Associated with:1 targets
0 immuno-relevant targets
8 immuno-relevant ligands
Synonyms
Inflammatory bowel disease
Database Links
Disease Ontology: DOID:0050589
OMIM: 266600

Targets

Ligands

Ligand Approved Immuno References Clinical comments
BMS-561392
Clinical Use: Potential treatment for overproduction of TNF alpha, such as rheumatoid arthritis (phase 2 trial) or inflammatory bowel disease [1]. Hoerver since this report there appears to have been no further development of this compound.
Immuno Disease Comments: An investigational ADAM17 inhibitor with potential to reduce TNFα production in TNF-driven conditions such as RA.
3beta-Hydroxy-20(29)-lupene
Immuno Disease Comments: Experimental compound with predicted application in inflammatory bowel diseases.
MRL-367
Immuno Disease Comments: Experimental compound with predicted application in inflammatory bowel disease.
MRL-248
Immuno Disease Comments: Experimental compound with predicted application in inflammatory bowel disease.
GSK583
Immuno Disease Comments: Experimental compound with predicted application in inflammatory bowel disease.
bihelical apoA-I mimetic peptide 5A
Immuno Disease Comments: Experimental compound with predicted application in inflammatory bowel disease.
etrasimod
Clinical Use: Etrasimod (APD334) is in Phase 2 extension study clinical trial in patients with moderately to severely active ulcerative colitis (see NCT02536404).
Immuno Disease Comments: Phase 2 clinical candidate for IBD patients (including UC and Crohn's disease) with active skin manifestations (see proof of concept study NCT03139032).
PF-06651600
Clinical Use: PF-06651600 has completed Phase 1clinical trial for inflammatory bowel disease (see NCT02309827). Phase 1 studies in rheumatoid arthritis, ulcerative colitis and alopecia areata are underway.
Immuno Disease Comments: Phase 1 clinical candidate for IBD (NCT02309827).

References

Show »

1. Grootveld M, McDermott MF. (2003) BMS-561392. Bristol-Myers Squibb. Curr Opin Investig Drugs, 4 (5): 598-602. [PMID:12833656]